Teva Parenteral Medicines Initiates Voluntary Nationwide Recall of Select Lots of Adrucil (Fluorouracil Injection, USP) 5 G/100 mL (50 mg/mL) Due To Particulate Matter

You are subscribed to Recalls, Market Withdrawals and Safety Alerts for U.S. Food & Drug Administration (FDA).

This information has recently been updated and is now available.

 

Teva Parenteral Medicines Initiates Voluntary Nationwide Recall of Select Lots of Adrucil (Fluorouracil Injection, USP) 5 G/100 mL (50 mg/mL) Due To Particulate Matter

07/27/2015 02:46 PM EDT

Teva Parenteral Medicines today announced a voluntary recall of six lots of Adrucil® (fluorouracil injection, USP) 5 g/100 mL (50 mg/mL) due to the potential presence of particulate matter identified as aggregate of silicone rubber pieces from a filler diaphragm and fluorouracil crystals. The recalled lots are as follows:

. For detailed information pertaining to this Recalls, Market Withdrawals and Safety Alerts message, please click the link at the beginning of this bulletin.

---

Manage your FDA Subscriptions:

• Update your preferences or unsubscribe
• Questions about this service? Please visit subscriberhelp.govdelivery.com
• Other inquiries? webmail@oc.fda.gov

---

This email was sent to filter@clubhouseb.com using GovDelivery, on behalf of: U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · Silver Spring, MD 20993 · 800-439-1420